Xanthine oxidase (XOD) inhibition has long been considered an effective anti-hyperuricemia strategy. To identify effective natural XOD inhibitors with little side effects, we performed a XOD inhibitory assay-coupled isolation of compounds from Smilacis Glabrae Rhizoma (SGR), a traditional Chinese medicine frequently prescribed as anti-hyperuricemia agent for centuries. Through the in vitro XOD inhibitory assay, we obtained a novel XOD inhibitor, 5-O-caffeoylshikimic acid (#1, 5OCSA) with IC₅₀ of 13.96 μM, as well as two known XOD inhibitors, quercetin (#3) and astilbin (#6). Meanwhile, we performed in silico molecular docking and found 5OCSA could interact with the active sites of XOD (PDB ID: 3NVY) with a binding energy of −8.6 kcal/mol, suggesting 5OCSA inhibits XOD by binding with its active site. To evaluate the in vivo effects on XOD, we generated a hyperuricemia mice model by intraperitoneal injection of potassium oxonate (300 mg/kg) and oral gavage of hypoxanthine (500 mg/kg) for 7 days. 5OCSA could inhibit both hepatic and serum XOD in vivo, together with an improvement of histological and multiple serological parameters in kidney injury and HUA. Collectively, our results suggested that 5OCSA may be developed into a safe and effective XOD inhibitor based on in vitro, in silico and in vivo evidence.

In this study, the chemical composition of different tissues of Rana temporaria chensinensis David derived from the same individual was analyzed by comparative approach. First, pre-column derivatization combined with high performance liquid chromatography (HPLC) was established to determine the content of 1-methyl hydantoin in samples, which used S1–S5 samples. The results indicated that 1-methyl hydantoin was determined in Oviductus Ranae (OR), Rana chensinensis ovum (RCO), Rana chensinensis meat (RCM), and Rana chensinensis skin (RCS), except for Rana chensinensis bone (RCB). Moreover, the content of it in RCS was the highest. In addition, the contents of six polyunsaturated fatty acids (PUFAs) in different tissues of Rana chensinensis were measured by HPLC, including eicosapentaenoic acid (EPA), α-linolenic acid (ALA), docosahexaenoic acid (DHA), arachidonic acid (ARA), linoleic acid (LA) and oleic acid (OA). The results indicated that OR, RCO, RCM, RCS, and RCB all contained the above six PUFAs. With the aid of chemometrics methods, the results of principal component analysis (PCA), hierarchical cluster analysis (HCA), and orthogonal partial least squares discriminant analysis (OPLS-DA) combined with the sequencing results of the total PUFAs content of each sample, showed that different tissues of Rana chensinensis could be divided into four categories, and the RCO sample was divided into one category because of the highest PUFAs content, which was a good source of PUFA. For comparison, OR and other tissue from the perspective of PUFAs, we also established OPLS-DA models of them. It could be found that the RCM was the most similar to the OR in the diversity and content of PUFAs. This study provided a theoretical basis for the further development and utilization of RCO, RCM, RCS, and RCB as by-products of OR.

Medicinal plants have long been used to manage hyperuricemia (HUA) and gout, with flavonoids identified as key bioactive components. However, the therapeutic effects of flavonoids on HUA remain inadequately characterized. Thus, we conducted a systematic review and meta-analysis to evaluate the impact of flavonoids on serum uric acid (UA) and xanthine oxidase (XOD) activity in animal models. A comprehensive literature search of the PubMed and Web of Science databases (January 2007–December 2024) identified 21 eligible studies involving 550 male mice. A random-effects meta-analysis revealed that flavonoid administration significantly reduced serum UA (standardized mean difference [SMD] = –2.22, 95% confidence interval (CI): –2.80 to –1.64; p < 0.001) and XOD activity (SMD = –1.79, 95% CI: –2.50 to –1.08; p < 0.001). Subgroup analyses indicated that chalcones, flavonols, and flavones exerted the most pronounced hypouricemic effects. Molecular docking of 28 flavonoids to XOD yielded binding affinities ranging from –8.4 to –10.9 kcal/mol, with molecular dynamics simulations confirming stable ligand–enzyme complexes; flavones exhibited the highest stability. Collectively, these data provide robust preclinical evidence that flavonoids ameliorate hyperuricemia via dual mechanisms of UA reduction and XOD inhibition, and support the further clinical development of flavonoids as potential natural agents for managing HUA.